ABSTRACT
Objective@#To investigate the effects of two different sorbents(Carbon perfusion apparatus and Resin perfusion apparatus)in Double plasma molecular absorb syetem for liver failure treatment.@*Methods@#A total of 152 cases with liver failure who were admitted to The Sixth People's Hospital of Zhengzhou, from June 2016 to May 2018 were selected and divided into DPMARS Carbon group (77 cases) and Resin group (75 cases). The two groups were observed in terms of liver function, prothrombin activity(PTA),Plasma albumin ,tumor necrosis factor alpha and interleukin-6 were detected and compared between the two groups before and after treatment.@*Results@#①The clinical symptoms improved in different degree in two groups, the recovery rate of Carbon cans Carbon perfusion apparatus group and Resin group separately were89.6% (69/77)、90.7% (68/75)(χ2 = 0.048, P = 0.975), there were no statistical differences. There were no statistical differences between the two groups in untoward reactions(χ2 = 0.235, P = 0.995), ②Compared with before treatment, TBil(t = 3.735, 3.728; P = 0.000, 0.000)、ALT(t = 5.117, 5.203; P = 0.000, 0.000)、TNF-α (t = 3.158, 3.094; P = 0.000, 0.002)、IL-6(t = 3.647, 3.559; P = 0.002, 0.003)decreased and ALB (t = 2.300, 3.065; P = 0.024, 0.003) increased significantly after treatment in both groups, and there were statistical differences. There were no signifiant differences in the changes in ALB(t = 0.316, 0.209; P = 0.657, 0.720) and PTA(t = 0.810, 0.843; P = 0.429, 0.516). ③After treatment, there were no signifiant differences in the changes in TBil、ALT、ALB、PTA、TNF-α、IL-6(t = 0.377、0.904、-1.133、-1.552、0.841、0.401; P = 0.952、0.283、0.826、0.094、0.154、0.457).@*Conclusion@#Double plasma molecular absorb syetem is effective in treating liver failure. Carbon perfusion apparatus or Resin perfusion apparatus can be combined with Specific bilirubin adsorption column for DPMARS in clinical treatment,and their effects are similar.
ABSTRACT
Background and objective Studies conducted across the world have reported that the rates of major adverse cardiac events (MACE) following the use of bioresorbable vascular scaffolds (BVS) are comparable to that noted with traditional drug eluting stents (DES). However, there is limited data on the immediate and medium-term clinical outcomes following the use of the Absorb BVS (Abbott Vascular, Santa Clara, SA) in the Indian context. This study was conducted to determine real-world evidence on the immediate and medium-term clinical outcomes in all patients undergoing percutaneous coronary intervention (PCI) with the Absorb BVS. Methods Data of all patients who were treated with Absorb BVS at our center were evaluated. Between December 2012 and October 2016, 142 patients underwent PCI with BVS. The MACE rates during hospitalization, at 30 days, 3 months, 6 months after PCI, and every 6 months thereafter were the primary endpoints evaluated with median follow up of 13 months. Results Mean age of the study participants was 53.7 ± 11.8 years. Intravascular ultrasound imaging was performed in 15.34% of patients. Predilatation and postdilatation were performed in 81.8% and 84.6% of scaffolds, respectively. There were no episodes of MACE during hospitalization. However, 1 BVS-related MACE was observed at the 1-month (0.7%) as well as at the ≥12 month (0.8%) follow up visits. At the 6- and 12-month follow up visits, 2 (1.5%) and 3 (2.5%) non-BVS-related MACEs, respectively, were recorded. Conclusion The use of Absorb BVS in this real-world experience was associated with very good immediate and medium-term clinical outcomes.
ABSTRACT
Bioresorbable scaffolds (BRS) represent a novel paradigm in the 40-year history of interventional cardiology. Restoration of cyclic pulsatility and physiologic vasomotion, adaptive vascular remodeling, plaque regression, and removal of the trigger for late adverse events are expected BRS benefits over current metallic drug-eluting stents. However, first-generation BRS devices have significant manufacturing limitations and rely on optimal implantation technique to avoid experiencing an excess of clinical events. There are currently at least 22 BRS devices in different stages of development, including many trials of device iterations with thinner (<150 µm) struts than first-generation BRS. This article reviews the outcomes of commercially available and potentially upcoming BRS, focusing on the most recent stages of clinical development and future directions for each scaffold type.
Subject(s)
Angioplasty , Cardiology , Drug-Eluting Stents , Vascular RemodelingABSTRACT
Abstract: Introduction: A case report describing the use of bio-absorbable vascular scaffolds in a patient with rare anomalous origin of right coronary artery. Case report: Male 71 years, ST-segment elevation myocardial infarction in the inferior region wall, thrombolysis with tenecteplase, with reperfusion criteria. Coronary angiography: left coronary system without angiographic lesions, right coronary artery with a significant lesion in the middle segment. An elective percutaneous coronary intervention was performed using 2 bio-absorbable vascular scaffolds (Absorb 3.5 x 28 mm joined in proximal segment with an Absorb 3.5 x 23 mm), posterior review with optical coherence tomography. Results: Discharged 24 hours later, remaining asymptomatic at 6 months follow-up. Conclusion: In this case, the significant stenosis of the artery involved was treated with the implantation of two bio-absorbable vascular scaffolds, obtaining an appropriate outcome after six months follow-up. This is the first report of a patient with anomalous origin of the right coronary artery treated with bio-absorbable vascular scaffolds in Mexico.
Resumen: Introducción: Se trata de un caso clínico que describe el uso de stents bioabsorbibles en un paciente con origen anómalo de arteria coronaria derecha de rara presentación. Caso clínico: Hombre de 71 años, con antecedente de infarto del miocardio con elevación del segmento ST en la cara inferior, sometido a trombolisis con tenecteplase, presentando criterios de reperfusión. El angiograma coronario reporta el sistema coronario izquierdo sin lesiones significativas, así como la arteria coronaria derecha con una lesión significativa en el segmento proximal a medio. Se realizó una intervención coronaria percutánea electiva con dos stents bioabsorbibles (Absorb 3.5 x 28 mm el cual se empalmó en el segmento proximal con un Absorb 3.5 x 23 mm), revisión posterior con tomografía de coherencia óptica con adecuada aposición. Resultados: Egresado 24 horas más tarde, permaneciendo asintomático a los seis meses de seguimiento. Conclusión: En este caso, la estenosis significativa de la arteria involucrada fue tratada con la implantación de dos stents bioabsorbibles, con la obtención de un resultado clínico apropiado después de seis meses de seguimiento. Éste es el primer informe de un paciente con un origen anómalo de la arteria coronaria derecha tratado con stents bioabsorbibles en México.
ABSTRACT
Objective To improve the pipeline which is the second grade of oxygen pressure reducer in order to reduce the oxygen resistance. Methods This device accesses oxygen storage devices in the original pipeline which absorbs oxygen in the atmospheric with the second grade pressure reducer. Results Accessing oxygen storage devices almost can eliminate the additional resistance which is produced by the second pressure reducer. Conclusion The accessing device fully meets the demand of the people with weak breathing, who accesses oxygen for oxygen therapy via the second grade pressure reducer. Meantime, the device expands the scope of services and efficacy of the medical equipment.
ABSTRACT
Objective To control the hazardous effects of excessive arsenic in drinking water on human health. Methods The experiment on the removal of excessive arsenic from drinking water by electric absorb technology (EST) was performed. Results The pilot experiment and experiment in situ showed that, after treatment by EST, the contents of arsenic in source water(0.06-0.33 mg/L) decreased to the levels of